N-hydroxy-6-methoxy-pyridine-3-carboximidoyl chloride | 1009562-89-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-hydroxy-6-methoxy-pyridine-3-carboximidoyl chloride
• 英文别名: N-hydroxy-6-methoxy-3-pyridinecarboximidoyl chloride；N-hydroxy-6-methoxy-pyridine-3-carboximidic chloride；N-Hydroxy-6-methoxy-3-pyridinecarboximidoyl chloride；N-hydroxy-6-methoxypyridine-3-carboximidoyl chloride
• CAS: 1009562-89-3
• 化学式: C₇H₇ClN₂O₂
• 分子量: 186.598
• InChiKey: VTWDULKIWHXWNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  54.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-hydroxy-6-methoxy-pyridine-3-carboximidoyl chloride 在 (N-benzyl-N-methyl) benzene sulfone iminium fluoride trifluoromethanesulfonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.02h， 生成 (Z)-N-(6-methoxypyridin-3-yl)morpholine-4-carbimidoyl fluoride
  参考文献：
  名称：

  通过模块化合成途径扩大氟甲脒的获取范围

  摘要：

  尽管氟甲脒结合了药物设计中最受重视的两种元素：氮和氟，但它是一种未被充分利用和研究的官能团。我们报告了通过原位生成的偕胺肟重排来实用和模块化合成氟甲脒。在室温下仅需 60 秒即可获得高产率，凸显了该协议的效率。此外，氟甲脒被证明是合成各种脲和氨基甲酸酯的有用中间体。

  DOI：

  10.1021/acs.orglett.4c00131
• 作为产物：
  描述：

  N-hydroxy-1-(6-methoxypyridin-3-yl)methanimine 在 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-hydroxy-6-methoxy-pyridine-3-carboximidoyl chloride
  参考文献：
  名称：

  通过模块化合成途径扩大氟甲脒的获取范围

  摘要：

  尽管氟甲脒结合了药物设计中最受重视的两种元素：氮和氟，但它是一种未被充分利用和研究的官能团。我们报告了通过原位生成的偕胺肟重排来实用和模块化合成氟甲脒。在室温下仅需 60 秒即可获得高产率，凸显了该协议的效率。此外，氟甲脒被证明是合成各种脲和氨基甲酸酯的有用中间体。

  DOI：

  10.1021/acs.orglett.4c00131

文献信息

• [EN] C-7 ISOXAZOLINYL QUINOLONE/NAPHTHYRIDINE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE C-7 ISOXAZOLINYL QUINOLONE/NAPHTHYRIDINE CONVENANT COMME AGENTS ANTI-BACTÉRIENS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010093341A1

  公开（公告）日：2010-08-19

  The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

  本发明涉及C-7异噁唑基喹啉/萘啶衍生物，可用作抗微生物化合物，包括含有这些衍生物的药物组合物以及将这些衍生物和药物组合物用作抗病原微生物的抗微生物剂，特别是对抗耐药菌。
• C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents
  申请人：Macielag Mark J.

  公开号：US20090029980A1

  公开（公告）日：2009-01-29

  The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

  本发明涉及C-7异噁唑基喹啉/萘啶衍生物，可用作抗微生物化合物，包括含有该衍生物的药物组合物以及将该衍生物和药物组合物用作抗病原微生物的抗微生物剂，特别是对抗耐药微生物。
• [EN] SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION<br/>[FR] AMINOTHIAZOLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA DGK ZÊTA POUR L'ACTIVATION IMMUNITAIRE
  申请人：BAYER AG

  公开号：WO2021214020A1

  公开（公告）日：2021-10-28

  The present invention covers aminothiazole compounds of general formula (I) : in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGKζ) regulated disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的氨基噻唑化合物：其中R1、R2、R3和R4如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病，特别是二酰基甘油激酶ζ（DGKζ）调节性疾病的药物组合物的用途，作为唯一药剂或与其他活性成分组合使用。
• C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
  申请人：Janssen Pharmaceutica NV.

  公开号：US07902227B2

  公开（公告）日：2011-03-08

  The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

  本发明涉及C-7异噁唑基喹啉/萘啶衍生物，作为抗微生物化合物，包括所述衍生物的制药组合物以及将所述衍生物和制药组合物用作抗病原微生物的抗微生物剂，特别是对抗耐药微生物。
• Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains
  作者：Hamish S. Sutherland、Adrian Blaser、Iveta Kmentova、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、Brian D. Palmer、William A. Denny、Andrew M. Thompson

  DOI：10.1021/jm901378u

  日期：2010.1.28

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.